A new study highlights the under-reporting of racial and ethnic data from pivotal trials for drugs that have received approval in Europe, which perhaps is one reason trial diversity has been less in the public spotlight there.
The study, from Tufts University’s Center for the Study of Drug Development (Tufts CSDD), appears in the May/June issue of...